INTRODUCTION
Lung cancer with epidermal growth factor receptor (EGFR)-activating mutations, such as exon 19 deletion and exon 21 L858R point mutation, responds to the EGFR-tyrosine kinase inhibitors (EGFR-TKIs) gefitinib and erlotinib. 1 Recent clinical trials demonstrated much longer progression-free survival for EGFR mutant lung cancer patients when treated with gefitinib compared with conventional chemotherapy. 2, 3 However, almost without exception, the responders relapse after various times due to acquiring resistance to EGFR-TKIs. 1, 4 The development of gatekeeper mutations, such as T315I in Abl, 5 D473H in SMO 6 and L1196M in ALK, 7 is the most common mechanism of acquired TKI resistance. 8 In cases of EGFR mutant lung cancer, EGFR T790M mutation is detected in about 50% of patients with acquired resistance to EGFR-TKIs. 4, 8, 9 T790M mutation results in increased EGFR affinity to adenosine triphosphate, reducing binding of EGFR-TKIs, and thus inducing resistance. 10 However, EGFR mutant lung cancer cells with T790M mutation are still dependent on EGFR-mediated signaling, 10 and therefore further elucidation of mutant EGFR-mediated signaling may facilitate the development of novel effective therapeutic strategies against lung cancer with EGFR mutations, including T790M gatekeeper mutation.
New generation EGFR-TKIs, such as irreversible EGFR-TKIs and mutant EGFR selective TKIs, were expected to overcome acquired resistance caused by T790M secondary mutation. [11] [12] [13] [14] [15] However, several irreversible EGFR-TKIs failed to meet primary end points in clinical trials in EGFR-TKI-refractory lung cancer and induced severe adverse effects, such as diarrhea, skin rush/acne, stomatitis and nail effect. 1, 16 More recently, a phase Ib trial of EGFR dual inhibition with irreversible EGFR-TKI afatinib plus anti-EGFR monoclonal antibody cetuximab indicated with a 40% objective response rate in 47 patients with EGFR-TKI acquired resistance, 17 suggesting that many tumors are still addicted to the EGFR signaling pathway, including EGFR T790M gatekeeper mutation in clinical trials. Therefore, new intensification treatment targeting EGFR signaling is expected to get for more clinical benefit, whereas the feasibility of these strategies should be evaluated carefully in clinical trials.
Receptor tyrosine kinases, such as EGFR, PDGFRs and VEGFRs, utilize several common downstream signaling pathways, including MAPK/ERK and PI3K/Akt, while each receptor shows different or specific biological activity after ligand stimulation. Scaffold proteins that can simultaneously interact with two or more protein binding partners are thought to ensure specificity as well as temporal regulation of signal transduction. Thus, scaffold proteins may be important targets for regulating receptormediated signaling. There is accumulating evidence that Akt signaling is essential for mediating survival signals in EGFR mutant lung cancer cells. 18, 19 Although several molecules, including KSP, 20 Paxillin, 21 RKIP, 22 and JIP-1, 23 are known to act as scaffolds for MAPK-ERK, 24 scaffold proteins for Akt have not been well documented. Recently, we reported Akt kinase-interacting protein1 (Aki1) as the first identified scaffold in the PI3K/PDK1/ Akt pathway. Aki1 selectively forms a complex with EGFR and Akt in response to EGF stimulation, mediates Akt activation by PDK1, and hence contributes to cell survival and proliferation. 25 However, Aki1, the scaffold proteins for therapeutic target in cancers, have yet to be identified.
In the present study, we examined whether Aki1 would act as a determinant of receptor signaling selectivity of mutant EGFR and could be a therapeutic target for EGFR mutant lung cancer, including that with T790M gatekeeper mutation.
RESULTS
High levels of Aki1 protein expression in EGFR mutant lung cancer cell lines As the first step to assess the involvement of Aki1 in EGFRmediating signal of lung cancer cells, we examined the expression of Aki1 protein and its associated proteins (PDK1, Akt and EGFR) in five human lung adenocarcinoma cells with or without EGFR mutations, comparing that in two human lung embryonic fibroblast cell lines, by western blotting (Figure 1a) . All of the cell lines examined expressed Aki1 and PDK1 protein at various levels. The levels of Aki1 tend to be higher in EGFR mutant lung cancer cell lines than in lung fibroblast cell lines.
EGFR was also detected in all lung cancer and fibroblast cell lines at various levels. Interestingly, phosphorylated EGFR was detected in EGFR mutant lung cancer cell lines, but not detected in EGFR wild-type lung cancer cell lines and fibroblast cell lines. The co-detection of Aki1 and phosphorylated EGFR in these cell lines suggested interactions between Aki1 and mutant EGFR because Aki1 was shown to bind preferentially to activated wild-type EGFR.
25
Aki1 constitutively associates with EGFR without ligand stimulation in EGFR mutant lung cancer cells To determine the role of Aki1 in the EGFR/PDK1/Akt pathway, we examined the association between Aki1 and EGFR by immunoprecipitation. Aki1 constitutively associated with EGFR in all three EGFR mutant lung cancer cell lines (Figure 1b) . Consistent with the results of previous studies, 25 Aki1 did not associate with IGF-1 R, irrespective of IGF-1 stimulation, indicating selective binding of Aki1 to EGFR (Figure 1b) . Moreover, treatment with EGFR-TKI did not affect the association between Aki1 and EGFR/PDK1/Akt (Supplementary Figure S1) . These results further suggest that Aki1 may be involved deeply in signal transduction through mutant EGFR.
Specific downregulation of Aki1 inhibits cell viability and induces cell apoptosis in EGFR mutant lung cancer cells To determine the role of Aki1 in EGFR mutant lung cancer cell lines, we used specific small interfering RNA (siRNA) for Aki1 knockdown. Treatment with Aki1-specific siRNA suppressed Aki1 protein expression, and more decreased the viability of EGFR mutant cells (PC-9, HCC827 and H1975) than EGFR wild-type cells (A549 and PC14PE6) (Figure 2a and Supplementary Figure S2) . To confirm the specificity of the Aki1 siRNA used, we constructed RNA interference (RNAi)-resistant Aki1 cDNA by mutating the sequence targeted by Aki1 siRNA without changing the amino acid sequence. Transfection of wild-type Aki1 or RNAi-resistant Aki1 resulted in increased expression of Aki1 protein in PC-9 cells (Supplementary Figure S3A) Figure S3C) , indicating the specificity of siRNA to Aki1. On the other hand, the effects of Aki siRNA in lung fibroblasts, MRC-5 and IMR-90, were only marginal (Figure 2a) , suggesting that Aki knockdown selectively inhibits viability of cancer cells with dependent EGFR signal, especially in EGFR mutant lung cancer cells. In addition, to rule out any bystander effect of the siRNA, we performed cell culture using two color labeling. We found that Aki1-1 siRNA did not show any discernible bystander effect. Therefore, we conclude that the bystander effect is not the primary mechanism by which the Aki1-1siRNA treatment inhibited tumor cell growth, under our experimental conditions (Supplementary Figure S5A and B) . Therefore, we focused solely on EGFR mutant lung cancer cells. Western blotting analyses indicated that Aki1 knockdown reduced phosphorylation of downstream molecules, Akt and S6, and increased the levels of the proapoptotic molecule, cleaved PARP (poly (ADP-ribose) polymerase; Figure 2b ), consistent with the decrease in cell viability. Furthermore, we also found that knockdown of Aki1 discernibly induced apoptosis in PC-9, HCC827 and H1975 cells (Figure 2c ).
We next assessed the effect of Aki1 inhibition, in comparison with EGFR inhibition, in EGFR mutant lung cancer cell lines. Like EGFR knockdown and erlotinib, Aki1 knockdown considerably inhibited viability of PC-9 and HCC827 cells with exon 19 deletion in EGFR. In addition, Aki1 knockdown inhibited viability of H1975 cells with exon 21 L858R and exon 20 T790M double mutations as potently as EGFR siRNA, whereas erlotinib had no effect ( Figures  3a and b) . These results suggest that targeting of Aki1 may be valuable for treating EGFR mutant lung cancer cells, especially with T790M gatekeeper mutation.
Aki1 knockdown inhibits tumor growth of lung cancer with EGFR T790M secondary mutation in vivo Next, we examined the antitumor potential of Aki1 siRNA against H1975 cells with EGFR T790M gatekeeper mutation in vivo. Intratumoral injection of either scramble or Aki1 siRNA complexed with invivofectamine was performed on days 5 and 8. In a previous report, MAGE-D1 gene knockdown by three direct injections of siRNA complicated with invivofectamine into the local region indicated 50% inhibition of protein expression. 26 Aki1 siRNA treatment dramatically inhibited tumor growth in comparison with control or scramble siRNA (Figures 4a and b) . We confirmed knockdown of Aki1 and the inhibition of downstream signaling molecule, S6, in tumors by western blotting (Figure 4c ). These results clearly indicated the therapeutic potential of Aki1 siRNA against lung cancer with EGFR T790M mutation in vivo.
Combined Aki1 and EGFR blockade strongly suppressed cell viability of lung cancer cells with EGFR T790M secondary mutation Irreversible EGFR-TKIs and mutant selective EGFR-TKIs were developed to overcome EGFR T790M gatekeeper mutationmediated resistance to erlotinib and gefitinib. Here, we examined whether Aki1 knockdown could augment the therapeutic efficacy of these new generation EGFR-TKIs. Irreversible EGFR-TKI, CL-387,785 and BIBW2992, and the mutant-selective EGFR-TKI, WZ4002, reduced the viability of H1975 cells, whereas erlotinib had no such effect. Aki1 knockdown suppressed cell viability and further augmented the various dose inhibitory effects of CL-387,785, BIBW2992 and WZ4002 ( Figure 5a and Supplementary Figure S4 ). Consistent with these findings, Aki1
Aki1, a target for EGFR mutant lung cancer T Yamada et al knockdown decreased the levels of Akt and S6 phosphorylation, and increased the level of Par-4 and cleaved PARP, when combined with WZ4002 ( Figure 5b ). These results suggest the usefulness of Aki1 knockdown combined with new generation EGFR-TKIs against lung cancer with EGFR T790M gatekeeper mutation.
Aki1 is frequently expressed in EGFR mutant lung cancer We next examined Aki1 expression in 56 clinical specimens obtained from 56 lung cancer patients with EGFR mutation (Figure 6a and Supplementary Table S1 ). To confirm the specificity of the Aki1 by immunohistochemical staining, we performed Aki1 antibody absorption test by Aki1 peptide. The staining of Aki1 was remarkably diminished by pretreatment of sections with an Aki peptide at 4 1C overnight, compared with saline treatment, indicating the specificity of the antibody which we used for Aki1 staining (Supplementary Figure S6) . Forty-two tumors were obtained from EGFR-TKI naive patients. Seven tumors were from patients who showed intrinsic resistance to the EGFR-TKIs, gefitinib or erlotinib. Another seven tumors were from patients who showed acquired resistance to EGFR-TKIs ( Figure 6a ). Of 42 EGFR-TKI naive tumors, the presence of Aki1 protein was scored as 2 þ in 31 tumors (74%), 1 þ in 8 tumors (19%), and -in 3 tumors (7%). Aki1 protein was detected diffusely in all of seven tumors with intrinsic resistance: 2 þ in 4 (57%), 1 þ in 3 (43%). Aki1 protein was detected diffusely in all of seven tumors with acquired resistance: 2 þ in 6 (86%), 1 þ in 1 (14%) (Figure 6a ). Aki1 was detected in all tumors with acquired resistance, including four tumors with EGFR T790M mutation (Supplementary Table S1 ). These findings suggest involvement of Aki1 in EGFR-mediating signaling in lung cancer with EGFR mutations, including T790M gatekeeper mutation.
DISCUSSION
The results of the present study indicated that Aki1 constitutively associates with mutant EGFR even in the presence of EGFR-TKI. Silencing of Aki1 induces apoptosis of EGFR mutant lung cancer cells, indicating that Aki1 has crucial roles in survival signal transduction in lung cancer cells with EGFR mutations. In a xenograft model, silencing of Aki1 markedly inhibited growth of lung cancer cells with EGFR T790M gatekeeper mutation. Furthermore, Aki1 was frequently expressed in tumor cells of EGFR mutant lung cancer patients. Notably, it was detected in all tumors with acquired resistance to gefitinib or erlotinib, suggesting that Aki1 is an ideal target for EGFR mutant lung cancer, especially in cases with acquired EGFR-TKI resistance due to EGFR T790M gatekeeper mutation. Although Aki1 associates with wild-type EGFR when activated by EGF, 25 it binds constitutively with mutant EGFR (Figure 1b ).
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Previous studies indicated enhanced kinase activity and transformation capabilities of EGFR in the presence of L858R or exon 19 deletion mutation. 27, 28 Crystal structure analysis of the L858R mutant EGFR showed that this substitution activates the kinase through disruption of autoinhibitory interactions, resulting in receptors with high kinase activity compared with wild-type EGFR. 10, 29, 30 Consistent with these observations, mutant EGFR was constitutively phosphorylated, while the levels were varied among cell lines used in the present study. Taken together, these results indicate that Aki1 binds constitutively with mutant EGFR because mutant EGFR is constitutively activated.
There is accumulating evidence that scaffold proteins maintain signaling specificity and facilitate the activation of pathway components. 24, 31, 32 We showed that Aki1 constitutively forms complexes with EGFR, PDK, and Akt in EGFR mutant lung cancer cells. As in EGFR non-mutated cancer cells, 25 Aki1 did not bind to IGF-1 R even after stimulation with IGF-1 in EGFR mutant cells, indicating that Aki1 is the determinant of receptor signaling selectivity for EGFR. In a phase II clinical trial, anti-IGF-1 R antibody improved the response rate of conventional chemotherapy in non-small-cell lung cancer. 33 However, the phase III trial was terminated because of a trend toward poorer overall survival in the group with anti-IGF-1 R antibody. A preliminary report of toxicity from a phase II trial with the anti-IGF-1 R antibody demonstrated severe adverse events, including hyperglycemia. 34 These findings indicated difficulty of targeting IGF-1 R in cancer. As Aki1 is an EGFR-selective scaffold protein, Aki1 inhibition may have advantage over non-selective inhibition of IGF-1 R or its downstream PI3K/Akt pathway in terms of safety.
EGFR-T790M gatekeeper mutation is associated with 50% of cases of acquired resistance to EGFR-TKIs in EGFR mutant lung cancer. 4, 8, 9 Recently, mutant-selective EGFR-TKIs were developed, which inhibit EGFR with not only activating mutations, such as exon 19 in-frame deletion and L858R point mutation, but also T790M resistant mutation. 35 As the inhibitors were reported to have less activity for non-mutated EGFR, they may overcome T790M-mediated resistance and reduce adverse events, including skin toxicity. We found not only that Aki1 inhibition further augmented the efficacy of mutant EGFR-selective TKI and irreversible EGFR-TKI, but also that Aki1 constitutively associated with EGFR regardless of treatment with EGFR-TKI. In addition, Aki1 was detected in all tumors with acquired resistance, including tumors with EGFR T790M mutation. Our findings indicated the necessity of development of efficient Aki1 inhibitors, and suggested that combined use of Aki1 inhibitors may increase the therapeutic effects and may reduce adverse events concerning EGFR blockade of new generation EGFR-TKIs in EGFR mutant lung cancer. 
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In conclusion, we demonstrated that Aki1 constitutively associates with EGFR activating mutation as well as T790M gatekeeper mutation has important roles as a determinant of receptor selective signaling for mutant EGFR, and mediates the survival signal to Akt. Our data provide a rationale for targeting Aki1 in EGFR mutant lung cancer patients, especially in cases with acquired resistance due to EGFR-T790M gatekeeper mutation. We are currently developing a drug delivery system for Aki1 siRNA and small compounds with Aki1 inhibitory activity.
MATERIALS AND METHODS

Cell lines and reagents
The PC-9 and HCC827 human lung adenocarcinoma cell lines with EGFRactivating mutation (deletion in exon 19) were purchased from ImmunoBiological Laboratories (Gunma, Japan) and American Type Culture Collection (Manassas, VA, USA), respectively. 36 The H1975 human lung adenocarcinoma cell line with EGFR-L858R/T790M double mutation 10 was kindly provided by Dr John D Minna (University of Texas Southwestern Medical Center). The A549 human lung adenocarcinoma cell line, which expresses wild-type EGFR, was purchased from American Type Culture Collection. PC14PE6 human lung adenocarcinoma cell line, which expresses wild-type EGFR, was kindly provided by Dr Isaiah J Fidler (MD Anderson Cancer Center, Houston, TX, USA). 37 The human lung embryonic fibroblast MRC-5 (P30-35) and IMR-90 (P20-25) cell lines were obtained from RIKEN Cell Bank (Ibaraki, Japan). H1975, PC-9, HCC827, A549, and PC14PE6 cells were cultured in RPMI 1640, and MRC-5 and IMR-90 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS), penicillin (100 units/ml) and streptomycin (50 mg/ml), in a humidified CO 2 incubator at 37 1C. All experiments were performed in medium supplemented with 10% FBS. Erlotinib hydrochloride was obtained from Roche Pharma AG (Basel, Switzerland). CL-387, 785 was purchased from Calbiochem (San Diego, CA, USA). BIBW2992 and WZ4002 were purchased from Seleck Chemicals (Houston, TX, USA). Human wildtype Aki1 cDNA in the pFLAG-CMV-2 vector was generated previously. 25 RNAi-resistant Aki1 cDNA in the pFLAG-CMV-2 vector was generated by mutating CAAACTC of Aki1 siRNA-targeting sequence to TAAGTTA without changing the amino acid sequence.
Immunoprecipitation and western blotting
Tumor cells were incubated in 10 ml of RPMI 1640 with 10% FBS for 1 h. The cells were then washed twice with phosphate-buffered saline (PBS), harvested in cell lysis buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate, 1 mM Na 3 VO 4 , 1 mg/ml leupeptin and 1 mM phenylmethylsulfonyl fluoride) and flash-frozen on dry ice. After allowing the cells to thaw, the cell lysates were collected with a rubber scraper, sonicated and centrifuged at 14 000 Â g (4 1C for 20 min). The total protein concentration was measured using a Pierce BCA Protein Assay Kit (Pierce, Rockford, IL, USA). Aliquots of 400 mg of total proteins were immunoprecipitated with the appropriate antibodies. In some experiments, tumor cells were incubated in 10 ml of RPMI 1640 with 0.1% FBS in the presence or absence of erlotinib (0.3 mM), CL-387, 785 (0.3 mM) for 48 h. In other experiments, tumor cells were incubated in 10 ml of RPMI 1640 with 0.1% FBS in the presence or absence of EGF (50 ng/ml) or IGF-1 (50 ng/ml) for 10 min. In some experiments, tumor cells were transfected with RNAi for 24 h incubation and then incubated in 10 ml of RPMI 1640 with 10% FBS in the presence or absence of WZ4002 (0.1 mM) for 1 h. Immune complexes were recovered with Protein G-Sepharose beads (Zymed Laboratories, San Francisco, CA, USA). For western blotting assay, immunoprecipitates or cell lysates were subjected to SDS-PAGE (Bio-Rad, Hercules, CA, USA) and the proteins were then transferred onto polyvinylidene difluoride membranes (Bio-Rad). The membranes were blocked with Blocking One (Nacalai Tesque, Kyoto, Japan) for 1 h at room temperature, and the blots were then incubated at 4 1C overnight with anti-phospho-EGFR (Y1068), anti-Akt
Scramble siRNA
Aki1-1 siRNA Aki1, a target for EGFR mutant lung cancer T Yamada et al cells were then used for proliferation assay, which was measured using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium) dye reduction method. An aliquot of MTT solution (2 mg/ml; Sigma, St Louis, MO, USA) was added to each well followed by incubation for 2 h at 37 1C. The media were removed and the dark blue crystals in each well were dissolved in 100 ml of dimethyl sulfoxide (DMSO). Absorbance was measured with an MTP-120 microplate reader (Corona Electric, Ibaraki, Japan) at test and reference wavelengths of 550 nm and 630 nm, respectively. The percentage of growth is shown relative to untreated controls. Aki1 and EGFR knockdown were confirmed by western blotting analysis. The target sequences of siRNAs were as follows: Aki1-1, 5'-AGGAGCAGTT CAAACTCTGCATCAA-3' (corresponding to nucleotides 2125-2168); Aki1-2, 5'-AACAAAGACAUCCAGAUCGCCAGGG-3'; EGFR, 5'-CGGAATAGGTATTGGT GAATTTAAA-3' (corresponding to nucleotides 1014-1038). Each experiment was performed at least in triplicate, and three times independently.
Cell apoptosis assay
Cell apoptosis induced by Aki1-1 siRNA, Aki1-2 siRNA or Scramble siRNA was detected with an Annexin V-FITC Apoptosis Detection Kit I (BD Biosciences Pharmingen, Heidelberg, Germany) in accordance with the manufacturer's protocols as we described previously. 36 The analysis was performed on a FACSCalibur flow cytometer with Cell Quest software (Becton Dickinson, Franklin Lakes, NJ, USA).
Xenograft studies in SCID mice and in vivo RNAi
Suspensions of H1975 cells (5 Â 10 6 cells per 100 ml of PBS) were injected subcutaneously into the flanks of 5-week-old male SCID mice (Nihon Clea Co., Ltd, Tokyo, Japan). Tumor size was measured using digital calipers and tumor volume was calculated as 0.5 Â length Â (width) 2 . All animal experiments complied with the Guidelines for the Institute for Experimental Animals, Kanazawa University Advanced Science Research Center (approval no. AP-081088).
After cell inoculation, 50 mg of either scramble or Aki1 siRNA complexed with Invivofectamine (Invitrogen) was injected intratumorally on days 5 and 8. Tumors were harvested on day 26. siRNA and Invivofectamine complex was prepared in accordance with the manufacturer's instructions (Invitrogen). Aki1 knockdown in tumor tissue was confirmed by western blotting analysis.
Patients
A total of 56 tumor specimens with EGFR-activating mutations were obtained from 56 lung adenocarcinoma patients with written informed consent at the Kanazawa University Hospital (Kanazawa, Japan), Aichi Cancer Center Hospital (Nagoya, Japan), Osaka Medical Center (Osaka, Japan) and National Cancer Center Hospital East (Chiba, Japan) in studies with Institutional Review Board approval. Of the 56 patients, 42 were EGFR-TKI naive, seven showed intrinsic resistance, and the remaining seven patients showed partial response to initial EGFR-TKI treatment. As intrinsic resistance is not yet clearly defined, in the present study, we defined intrinsic resistant tumors as follows: response to treatment with an EGFR-TKI as defined by either documented stable disease or progressive disease (RECIST). Data for specimens from the seven patients who showed intrinsic resistance were obtained before EGFR-TKI treatment. For the seven patients who showed acquired resistance, tumor specimens were available after the development of acquired resistance to EGFR-TKI. Tumors with acquired resistance were defined as described previously. 38 Four of seven tumors from seven patients who showed acquired resistance had T790M secondary mutation.
Histology and immunohistochemistry
Immunohistochemical staining was carried out on formalin-fixed, paraffinembedded tissue sections of lung adenocarcinoma specimens. Sections 4-mm thick were deparaffinized in xylene and rehydrated in decreasing concentrations of ethanol. After blocking the endogenous peroxidase activity with 3% aqueous H 2 O 2 solution for 12 min, the sections were treated with 5% normal horse serum. The sections were then reacted with primary antibody (1:100 dilution, rabbit polyclonal anti-CC2D1A antibody; Sigma-Aldrich Corp., St Louis, MO, USA) at 4 1C overnight. After washing with PBS, the sections were treated with biotin-conjugated anti-rabbit IgG (1:200 dilution) for 30 min at room temperature and allowed to react for 30 min with avidin-biotin-peroxidase complex (ABC) using a Vectastain ABC kit (Vector Laboratories, Burlingame, CA, USA). The DAB (3,3'-diaminobenzidine tetrahydrochloride) Liquid System (DakoCytomation, Glostrup, Denmark) was used to detect immunostaining. Omission of primary antibodies served as negative control.
Evaluation of immunohistochemical results
Aki1 immunoreactivity was evaluated as the percentage of cancer cells with positive cytoplasmic staining (0, o5%; 1 þ , 5%-50%; 2 þ , 450%). Positive cells were defined as those with staining intensity that was the same or greater than that of normal bronchial epithelium (Figure 6b) . Evaluation was performed independently by two investigators (TY, HU) who were blind to individual clinical information about specimens.
Statistical analysis
The statistical significance of differences was analyzed by one-way ANOVA performed with GraphPad Prism Ver. 4.01 (GraphPad Software, Inc., San Diego, CA, USA). In all analyses, Po0.05 was taken to indicate statistical significance.
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